Dr. Vivek Kumar Dwivedi
M.Sc. & Ph.D
Experience: 12 Years
Dr. Vivek Kumar Dwivedi has more than 11 years research experiences in areas of clinical, preclinical and pharmaceutical products development. Dr. Dwivedi completed his master degree and doctorate degree in biochemistry from University of Lucknow, Lucknow. Dr. Dwivedi has been successfully established various herbal drugs especially in liver, haemorrhoids, arthritis and stress disorders. Dr. Dwivedi has get training as Study Director from National Good Laboratory Compliance Monitoring authorty (NGCMA), under department of Science & Technology, New Delhi. Dr. Dwivedi has been published more than 100 research articles in National & International repute journals and presented his research work on national and International platform in conferences/ Symposia. He has editorial board members of various scientific journals. He has conducted various toxicological and efficacy studies of various ayurvedic products for scientific support. He also given scientific supports through research for various other traditional medicine especially in the field of ayurveda.
Memberships & Certifications:
As Executive Editor member of International journal of drug development research peer review
As Associate Editor member of Internationale Pharmaceutica Sciencia (IPS) peer review Journal.
Member secretary of animal ethical committee, Venus medicine Research Centre Baddi.H.P
Research Publications:
Evaluation of comparative efficacy of wound healing, antioxidant,anti- inflammatory and antibacterial properties of Sanovul, Hydroheal and Becaplermin drugs in diabetic rats. International Journal of Pharmacy,104 242-252 Year-2013
Comparative wound healing efficacy of Ampucare and Becaplermin in diabetic rat”. African Journal of Pharmacy and Pharmacology, 6(12) 883-892, Year-2012
Comparative Study of CSE1034 and Ceftriaxone in Pneumonia Induced Rat model”. Clinical and Experimental Pharmacology 2(1): 1-8. Year-2012
Prevention of cadmium toxicity by ceftriaxone plus sulbactam with VRP1034 in rats” Drug Metabolism and Toxicology, 3(5): 1-8. Year-2012
Protective role of ceftriaxone plus sulbactam with VRP1034 on oxidative stress , haematological , enzymatic parameters in cadmium toxicity induced rat model ” Interdisciplinary toxicology , 3(5): 1-8. Year-2012
Chelating ability of Sulbactomax drug in arsenic intoxication” African Journal of Biochemistry Research Vol. 5(10), pp. 307-314, Year-2011
Comparative Safety Evaluation of Potentox ® vs Co-adminstartion of cefpime and amikacin in healthy albino rat”. IJDDR. 3(3) 348-355 (under press) Year-2011
Pharmacokinetic study of sulbactomax J. Toxicol. Sci.,35 (4): 459-464. PMID: 20686332 Year-2010
Sub-acute Toxicity Study of a New Aminoglycoside Etimicin Sulphate in Swiss Albino Mice J. Toxicol. Sci., 35 (4) 479- 489 Year-2010
In vitro penetration rate and efficacy of trios in arthritis induced rat model.” Aus. J. Basic Appl. Sci.,4 (7): 2068 -2080. Year -2010
Comparative efficacy of ampucare and silversulphadiazine against burn wound rat.” J. Appl. Sci. Res., 6(6): 674-682. Year-2010
Plasma cytokines and trace element level in severe burn rat model with special reference to wound healing potential of Ampucare” Res. J. Immunol., 3 (1): 22-30. Year-2010
Evaluation of Vancoplus versus Ceftriaxone against Cephalosporin Resistance MRSA Strain in Experimental Meningitis Model. Cardiovasc Hematol Disord Drug Targets. 10(2): 138-142. PMID: 20350284 Year-2010
Sub acute toxicity study of Etimycin sulphate in wister rat . Int. J. Pharm Sci Drug Res. 2(2): 120-122. Year-2010
Comparative Toxicity Profile Study of Mebatic vs. Ofloxacin, Ornidazole and Metronidazole Drugs in Rat Model” Asian. J. Biochem. 5 (2): 78-88. Year-2010
Efficacy of Ampucare: A Novel Herbal Formulation for Burn wound healing vs Other Burn Medicines”. Asian J. Biol. Sci. 3 (1):18-27. Year-2010
Improvement of blood brain barrier and antioxidant enzyme activity by immunox-V drug in meningitis”. Int. J. drug dev Res. 2 (1): 54-61. Year-2010
Effect of tobracef in carbapenem resistant pneumonia infection”. ”. Int. J. drug dev Res. 2 (1): 68-78. Year-2010
Efficacy evaluation of ampucare in comparison with silver sulfadiazine in burn wound healing in rats”. Int. J. drug dev Res. 2 (1): 85-88. Year-2010
In vitro tissue penetration study of sulbactomax : A novel fixed dose combination of ceftriaxone and sulbactam in rat”. Int. J. drug dev Res. 2 (1): 141-147. Year-2010
Protective role of acnano drug in acne vulgaris”. Int. J. drug dev Res. 2 (1): 148-156. Year-2010
Recovery of antioxidant level during intra-abdominal infection in mice by fixed dose combination of Ceftriaxone –Vancomycin”. J. Applied. Biosci., 35 (2): 138-145. Year-2009
Potentox reduces biochemical and inflammatory response in Osteomyelitis Infection.” (on line in Int. J. Osteophoresis Meta Dis, Volume: 4 (1 ): Page No.: 26-36 Year-2009
Toxicological effect of Bortezomib in wister rats”. Word J. Inno. Med. 1(1): 49-57. (Review article) Year-2009
Evaluation of Neuroprotective Effect of Glycerol, Mannitol, Neurotol and Neurotol Plus in Ischemic Brain Injury in Rats” Res. J. Neurology Year-2009
Therapeutic Efficacy of Ofloxacin and Ornidazole vs Mebatic : Toxicity Profile and Antioxidant Defense Study”. Research J. Parasitology 4 (3): 79-86 Year-2009
Fixed Dose Combination of Cefepime plus Amikacin (Potentox) Inhibits Pneumonia Infection”. Experimental lung Research, 35 (7) 621 – 629. PMID: 19842849 Year-2009
Diffusion of Sulbactomax and Ceftriaxone into Cerebrospinal Fluid of Meningitis Induced Rat Model” Int. J. Pharmacology., 5 (5): 307-312. Year-2009
Antioxidant and Blood Brain Barrier status in Cerebrospinal fluid of Bacterial Meningitis rat model after vancoplus treatment” Journal of Medical Sciences 9 (4): 194-201. Year-2009
Efficacy of Vancoplus against Intra Abdominal Infected Mice: A Novel Fixed Dose Combination of Ceftriaxone plus Vancomycin” J. Biol. Sci.2009; 9 (7): 665-671. Year-2009
Comparative Antioxidant Level in Renal and Liver Tissues of Mice Treated with Fixed Dose Combination of Cefepime-Amikacin Reconstituted in Solvent vs Water for Injection” Curr. Drug.Therapy. 4, (3) 174-178. Year-2009
Fixed Dose Combination of Ceftazidime plus Tobramycin act as Free Radical Scavenger in Liver of Mus musculus mice” Current Enzyme Inhibition., 5 (5), 171-175 Year-2009
Nephrotoxicity Reduction by Ceftriaxone plus Vancomycin (Vancoplus) Reconstituted with VRP 1020 in blood of Mus musculus mice”. J. Pharmacol.Toxicol. 4 (3): 107-116.Year-2009
Comparative Antimicrobial activity of Ceftazidime,Tobramycin and their fixed dose combination in some pathogenic microorganisms”. Curr. Drug.Therapy. 4 (2): 148-151. Year-2009
Comparative In vitro Antimicrobial Activity of Pantoprazole, Tetracycline and a Fixed Dose Combination in Helicobacter pylori Infection”. Curr. Drug.Therapy. 4 (2): 106-110 Year-2009
Ceftriaxone- Vancomycin drug toxicity reduction by VRP 1020 in Mus musculus mice”. Current Clin. Pharmacol. 4 (2): 95-101 PMID: 19442074 Year-2009
Nephrotoxicity Reduction by Fixed Dose Combination of Cephalosporins and Aminoglycosides in Mus musculus mice”. Asian J. of Biochem. 4 (1):13-21. Year-2009
Anti Oxidant Property of New Cephalosporin-Aminoglycodside Fixed Dose Combination”. Curr. Drug Therapy. 4 (1): 2-6. Year-2009
In vitro microbial efficacy of Sulbactomax, a novel fixed dose combination of Ceftriaxone Sulbactam and Ceftriaxone alone”. Curr. Drug Therapy., 4 (1): 73-77. Year-2009
Fixed Dose Combination of Cefepime plus Amikacin Prevent Oxidative Stress in Liver of Mus musculus mice”. Current Clin.Pharmacol. 3, (3): 211-4. PMID: 18781908 Year-2008
In vitro antimicrobial activity of cefepime, amikacin and their fixed dose combination against some pathogenic bacteria”. J. Ecophysiol. Occup.Hlth. 8: 161-165. Year-2008
Toxicological evaluation of ampucare: acute oral toxicity in wistar rats. J. Ecophysiol. Occup.Hlth. 8 (1-2): 27-30. Year-2008
Clinical trial survey report of ampucare done on patients with different wounds. J. Ecophysiol. Occup.Hlth. 8 (1-2): 89-97. Year-2008
Theraputic role of ampucare in alterations of antioxidant enzymes activities and wound healing effect in Mus musculus mice” J. Ecophysiol. Occup.Hlth. 8: 167-176. Year-2008
Status of some free radical scavenging enzymes in the patient of myocardial infarction”. In. J.Enz. Inhibition &Med. Chem. 21(1): 43-46. PMID: 16570504 Year-2008
Effect of Vitamin E on platelet enzymatic antioxidants in the patients of myocardial infarction”. Ind. J. Biochem. 20 (1): 21-25. Year-2005
Chelation in metal intoxication XLVI: Synthesis of some alpha-mercapto-b substituted aryl acrylic acids and their in vitro cadmium Chelating ability”. Biomed. Environ. Sci. 17 (1): 27-32. PMID: 15202861 Year-2004
Reversal of cadmium induced oxidative stress by chelating agents, anti oxidant their combination in rat”. Toxicol. letter. 145 (3): 211-217. PMID: 14580892 Year-2003
Effect of vitamin E on the tachycardia of medically treated patients with ischemic cardiac disorders”.Asia pacific. J . pharmacol. 16 (1): 39-39. Year-2002
Occupational lead poisoning among Indian silver refiners”. Ind. J. Occup and Environ Med. 15 (3): 153- 157. Year-2001
